Bay Space biotech SonoThera is effervescent to a medical boil after elevating a $125 million collection B with the backing of a number of the largest names in pharma.
Vida Ventures led the elevate, with the enterprise arms of UCB, Bayer, Otsuka Pharmaceutical and Johnson & Johnson all pitching in to help SonoThera’s distinctive supply system for genetic medicines.
SonoThera will use the elevate to push its lead candidate for Duchenne muscular dystrophy (DMD) and an autosomal dominant polycystic kidney illness program into the clinic, the biotech introduced in a June 10 launch.
The Massive Pharma curiosity stems from the potential for SonoThera’s know-how to unravel long-standing issues with conventional supply programs and produce genetic medicines to larger affected person populations, the biotech’s co-founder and CEO, Kenneth Greenberg, Ph.D., advised Fierce Biotech.
Viral vectors, the basic shuttle for gene therapies, are particularly susceptible to security issues reminiscent of liver toxicity and are restricted to a single dose due to recognition from the immune system, Greenberg defined. Each viruses and lipid nanoparticles additionally wrestle with complicated manufacturing processes, and may’t match giant quantities of DNA or RNA directly.
“A lot of the giant pharmas have been battling towards these identical challenges with their inside packages,” Greenberg mentioned. Additionally they acknowledge that SonoThera’s method “might permit the applying of gene remedy into persistent prevalent illnesses with a lot higher populations than uncommon illness[s].”
SonoThera’s resolution was invented by the corporate’s chief scientific officer and co-founder Steve Feinstein, M.D., again within the Nineteen Nineties. A heart specialist, Feinstein observed there was no strategy to produce distinction when utilizing ultrasound on the center, making imaging troublesome.
He created microbubbles as a strategy to higher view the blood-pumping organ, Greenberg advised Fierce. “He created all the area of distinction ultrasound by inventing the primary two FDA-approved microbubbles.”
It wasn’t lengthy till Feinstein acknowledged that the tiny bubbles is also used to assist ship medicines, and he, Greenberg and the opposite co-founders teamed as much as launch the corporate in 2022.
The method works like this, Greenberg mentioned: bare DNA or RNA is infused into the affected person’s physique alongside a stream of microbubbles. Ultrasound is then beamed onto the goal organ, which prompts the bubbles and causes them to open gaps within the blood vessels that function a path to the organ’s tissues. The identical ultrasound, the parts of that are all already established and FDA authorised, then makes the bubbles pop, opening pores within the organ’s cells that the genetic payload can slip by.
The entire process might be carried out in underneath an hour, in response to SonoThera’s launch.
“We actually wished to construct a platform that will allow affected person entry and adoption by the medical group with out having novel {hardware} and extra regulatory hurdles,” the CEO mentioned.
With $125 million extra now within the protected, the most important take a look at is about to return for SonoThera’s distinctive approach. The biotech plans to launch its DMD medical trial subsequent yr, utilizing its bubble-assisted supply to ship the full-length dystrophin gene to sufferers.
Dystrophin is the important thing muscle protein missing in DMD, however the gene that makes it’s too giant to suit into conventional adeno-associated virus (AAV) or nanoparticle vectors. That is why current medicines, like Sarepta Therapeutics’ Elevidys, as a substitute use a shortened type of the gene, or why different approaches attempt to goal particular disease-causing mutations.
“It’s over a 13-kilobase payload, which is basically about 3 times bigger than you’ll be able to match into an AAV vector,” Greenberg mentioned. “We’re not conscious of some other firm that’s trying to ship full-length dystrophin.”
